Identification of new genes associated with breast cancer progression by gene expression analysis of predefined sets of neoplastic tissues

International Journal of Cancer

Volumn 123, Issue 6, 2008, Pages 1327-1338

  Cimino, Daniela ^a,b,g   Fuso, Luca ^a,b   Sfiligoi, Christian ^a,f   Biglia, Nicoletta ^a,b   Ponzone, Riccardo ^a,b   Maggiorotto, Furio ^a,b   Russo, Giandomenico ^c   Cicatiello, Luigi ^d   Weisz, Alessandro ^d,e   Taverna, Daniela ^a,b,g   Sismondi, Piero ^a,b   De Bortoli, Michele ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e c/o CEINGE Biotecnologie Avanzate   (Italy)

^f MOLINETTE HOSPITAL   (Italy)

^g Molecular Biotechnology Center   (Italy)

Author keywords

Breast cancer; Gene expression; Microarray analysis; Prognostic

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; KERATIN; SERINE PROTEINASE INHIBITOR; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 49749106025     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23660     Document Type: Article

References (67)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
3. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 2002;347:1999-2009.
4. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
5. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-8.
6. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002;4:R3.
7. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Portengen H, Dorssers LC, Klijn JG, Berns EM. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005;23:732-40.
8. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sorlie T, Dai H, He YD, van't Veer LJ, Bartelink H, van de Rijn M, Brown PO, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA 2005;102:3738-43.
9. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-23.
10. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
11. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 2004;351:2817-26.
12. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM. Concordance among gene-expression-based predictors for breast cancer. New Engl J Med 2006;355:560-9.
13. Miller LD, Liu ET. Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. Breast Cancer Res 2007;9:206.
14. Son CG, Bilke S, Davis S, Greer BT, Wei JS, Whiteford CC, Chen QR, Cenacchi N, Khan J. Database of mRNA gene expression profiles of multiple human organs. Genome Res 2005;15:443-50.
15. Baldi P, Long AD. A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes. Bioinformatics 2001;17:509-19.
16. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001;98:5116-21.
17. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
18. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Scei USA 2005;102:13550-5.
19. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24.
20. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-72.
21. Frank E, Hall M, Trigg L, Holmes G, Witten IH. Data mining in bioinformatics using Weka. Bioinformatics 2004;20:2479-81.
22. Peng X, Wood CL, Blalock EM, Chen KC, Landfield PW, Stromberg AJ. Statistical implications of pooling RNA samples for microarray experiments. BMC Bioinformatics 2003;4:26.
23. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and. S100A11 are all overexpressed in common cancers. Histopathology 2005;46:256-69.
24. Koster A, Landgraf S, Leipold A, Sachse R, Gebhart E, Tulusan AH, Ronay G, Schmidt C, Dingermann T. Expression of oncogenes in human breast cancer specimens. Anticancer Res 1991;11:193-201.
25. Folgueira MA, Brentani H, Katayama ML, Patrao DF, Carraro DM, Mourao Netto M, Barbosa EM, Caldeira JR, Abreu AP, Lyra EC, Kaiano JH, Mota LD, et al. Gene expression profiling of clinical stages II and III breast cancer. Braz J Med Biol Res 2006;39:1101-13.
26. Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD, Robertson KD. Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis 2006;27:1341-8.
27. Debniak T, Scott R, Masojc B, Serrano-Fernandez P, Huzarski T, Byrski T, Debniak B, Gorski B, Cybulski C, Medrek K, Kurzawski G, van de Wetering T, et al. MC1R common variants. CDKN2A and their association with melanoma and breast cancer risk. Int J Cancer 2006;119:2597-602.
28. Redondo M, Villar E, Torres-Munoz J, Tellez T, Morell M, Petito CK. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000;157:393-9.
29. Manni A, Astrow SH, Gammon S, Thompson J, Mauger D, Washington S. Immunohistochemical detection of ornithine-decarboxylase in primary and metastatic human breast cancer specimens. Breast Cancer Res Treat 2001;67:147-56.
30. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 2004;6:R478-87.
31. Chintamani Jha BP, Bhandari V, Bansal A, Saxena S, Bhatnagar D. The expression of mismatched repair genes and their correlation with clinicopathological parameters and response to neo-adjuvant chemotherapy in breast cancer. Int Semin Surg Oncol 2007;4:5.
32. Wirtenberger M, Tchatchou S, Hemminki K, Klaes R, Schmutzler RK, Bermejo JL, Chen B, Wappenschmidt B, Meindl A, Bartram CR, Burwinkel B. Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer. Carcinogenesis 2006;27:593-8.
33. Simins AB, Weighardt H, Weidner KM, Weidle UH, Holzmann B. Functional cloning of ARM-1, an adhesion-regulating molecule upregulated in metastatic tumor cells. Clin Exp Metastasis 1999;17:641-8.
34. Suefuji Y, Sasatomi T, Shichijo S, Nakagawa S, Deguchi H, Koga T, Kameyama T, Itoh K. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients. Br J Cancer 2001;84:915-9.
35. Ito Y, Yoshida H, Uruno T, Takamura Y, Miya A, Kuma K, Miyauchi A. Expression of cdc25A and cdc25B phosphatase in breast carcinoma. Breast Cancer 2004;11:295-300.
36. Suh KS, Crutchley JM, Koochek A, Ryscavage A, Bhat K, Tanaka T, Oshima A, Fitzgerald P, Yuspa SH. Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers. Clin Cancer Res 2007;13:121-31.
37. Luftner D, Mesterharm J, Akrivakis C, Geppert R, Petrides PE, Wernecke KD, Possinger K. Tumor type M2 pyruvate kinase expression in advanced breast cancer. Anticancer Res 2000;20:5077-82.
38. Ugolini F, Charafe-Jauffret E, Bardou VJ, Geneix J, Adelaide J, Labat-Moleur F, Penault-Llorca F, Longy M, Jacquemier J, Birnbaum D, Pebusque MJ. WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene 2001;20:5810-7.
39. Li X, Cowell JK, Sossey-Alaoui K. CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer. Oncogene 2004;23:1474-80.
40. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, Hajduch M, Murray P, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007;7:55.
41. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006;10:529-41.
42. Zhao C, Yasui K, Lee CJ, Kurioka H, Hosokawa Y, Oka T, Inazawa J. Elevated expression levels of NCOA3. TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 2003;98:18-23.
43. Yamamura J, Miyoshi Y, Tamaki Y, Taguchi T, Iwao K, Monden M, Kato K, Noguchi S. mRNA expression level of estrogen-inducible gene, α1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers. Cancer sci 2004;95:887-92.
44. Garcia-Bassets I, Kwon YS, Telese F, Prefontaine GG, Hutt KR, Cheng CS, Ju BG, Ohgi KA, Wang J, Escoubet-Lozach L, Rose DW, Glass CK, et al. Histone methylation-dependent mechanisms impose ligand dependency for gene activation by nuclear receptors. Cell 2007;128:505-18.
45. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004;2:E7.
46. West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, Zuzan H, Olson JA, Jr, Marks JR, Nevins JR. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci USA 2001;98:11462-7.
47. Hurlimann J, van Melle G. Prognostic value of serum proteins synthesized by breast carcinoma cells. Am J Clin Pathol 1991;95:835-43.
48. Joseph J, Cardesa A, Carreras J. Creatine kinase activity and isoenzymes in lung, colon and liver carcinomas. Br J Cancer 1997;76:600-5.
49. Vyssokikh MY, Brdiczka D. The function of complexes between the outer mitochondrial membrane pore (VDAC) and the adenine nucleotide translocase in regulation of energy metabolism and apoptosis. Acta Biochim Pol 2003;50:389-404.
50. Valdez BC, Wang W. Mouse RNA helicase II/Gu: cDNA and genomic sequences, chromosomal localization, and regulation of expression. Genomics 2000;66:184-94.
51. Westermarck J, Weiss C, Saffrich R, Kast J, Musti AM, Wessely M, Ansorge W, Seraphin B, Wilm M, Valdez BC, Bohmann D. The DEXD/H-box RNA helicase RHII/Gu is a co-factor for c-Jun-activated transcription. EMBO J 2002;21:451-60.
52. Roy S, McPherson RA, Apolloni A, Yan J, Lane A, Clyde-Smith J, Hancock JF. 14-3-3 facilitates Ras-dependent Raf-1 activation in vitro and in vivo. Mol Cell Biol 1998;18:3947-55.
53. Thorson JA, Yu LW, Hsu AL, Shih NY, Graves PR, Tanner JW, Allen PM, Piwnica-Worms H, Shaw AS. 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity. Mol Cell Biol 1998;18:5229-38.
54. Won J, Kim DY, La M, Kim D, Meadows GG, Joe CO. Cleavage of 14-3-3 protein by caspase-3 facilitates bad interaction with Bcl-x(L) during apoptosis. J Biol Chem 2003;278:19347-51.
55. Nomura M, Shimizu S, Sugiyama T, Narita M, Ito T, Matsuda H, Tsujimoto Y. 14-3-3 Interacts directly with and negatively regulates proapoptotic Bax. J Biol Chem 2003;278:2058-65.
56. Salles B, Calsou P, Frit P, Muller C. The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol Biol 2006;54:185-93.
57. Liang F, Lee SY, Liang J, Lawrence DS, Zhang ZY. The role of protein-tyrosine phosphatase IB in integrin signaling. J Biol Chem 2005;280:24857-63.
58. Byon JC, Kusari AB, Kusari J. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol Cell Biochem 1998;182:101-8.
59. Stoll BA. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 2002;26:747-53.
60. Boudier C, Cadene M, Bieth JG. Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin. Biochemistry 1999;38:8451-7.
61. Zhang D, Simmen RC, Michel FJ, Zhao G, Vale-Cruz D, Simmen FA. Secretory leukocyte protease inhibitor mediates proliferation of human endometrial epithelial cells by positive and negative regulation of growth-associated genes. J Biol Chem 2002;277:29999-30009.
62. Devoogdt N, Hassanzadeh Ghassabeh G, Zhang J, Brys L, De Baetselier P, Revets H. Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci USA 2003;100:5778-82.
63. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K. Use of serum secretory leukocyte protease inhibitor levels in patients to improve specificity of ovarian cancer diagnosis. Gynecol Oncol 2005;96:516-9.
64. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
65. Wang N, Thuraisingam T, Fallavollita L, Ding A, Radzioch D, Brodt P. The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res 2006;66:3062-70.
66. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Cancer lett 2007;256:1-24.
67. Laine A, Davril M, Hayem A. Interaction between human serum alpha 1-antichymotrypsin and human leukocyte cathepsin G. complex formation and production of a modified inhibitor. Biochem Biophys Res Commun 1982;105:186-93.